Additional funding for CROSSJECT from BARDA

CROSSJECT, a specialty pharmaceutical company, announced an additional $11.3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) for the development of ZEPIZURE®. This funding brings the total to $43.3 million. It supports the regulatory and manufacturing steps toward obtaining FDA emergency and marketing authorizations.

The company has made significant progress, including the validation of several compliant batches and a facility audit. Upon approval, it will purchase 360,000 ZENEO® Midazolam auto-injectors for $60.84 million.

Patrick Alexandre, Chairman of the Board, expressed his gratitude to BARDA, affirming CROSSJECT's confidence in its partnership to meet regulatory requirements and move towards commercial production.